- Home
- NAAS vs SKYE Comparison
NAAS vs SKYE Comparison
Compare NAAS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | SKYE |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1M | 44.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAAS | SKYE |
|---|---|---|
| Price | $3.45 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 32.6K | ★ 412.0K |
| Earning Date | 03-31-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,817,052.00 | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.96 | $0.76 |
| 52 Week High | $40.32 | $5.75 |
Technical Indicators
Market Signals| Indicator | NAAS | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 26.94 |
| Support Level | $3.31 | $0.82 |
| Resistance Level | $3.65 | $0.95 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 20.10 | 7.80 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.